SG11202002220TA - Antibody variants - Google Patents
Antibody variantsInfo
- Publication number
- SG11202002220TA SG11202002220TA SG11202002220TA SG11202002220TA SG11202002220TA SG 11202002220T A SG11202002220T A SG 11202002220TA SG 11202002220T A SG11202002220T A SG 11202002220TA SG 11202002220T A SG11202002220T A SG 11202002220TA SG 11202002220T A SG11202002220T A SG 11202002220TA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody variants
- variants
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17191989.7A EP3456738B1 (de) | 2017-09-19 | 2017-09-19 | Antikörpervarianten |
| PCT/EP2018/074522 WO2019057564A1 (en) | 2017-09-19 | 2018-09-11 | ANTIBODY VARIANTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002220TA true SG11202002220TA (en) | 2020-04-29 |
Family
ID=59923275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002220TA SG11202002220TA (en) | 2017-09-19 | 2018-09-11 | Antibody variants |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11999781B2 (de) |
| EP (3) | EP3456738B1 (de) |
| JP (2) | JP7240385B2 (de) |
| KR (1) | KR20200053514A (de) |
| CN (1) | CN111094343B (de) |
| AR (1) | AR113303A1 (de) |
| AU (1) | AU2018337495B2 (de) |
| BR (1) | BR112020005482A2 (de) |
| CA (1) | CA3075959A1 (de) |
| CL (1) | CL2020000721A1 (de) |
| CO (1) | CO2020003260A2 (de) |
| CR (2) | CR20210205A (de) |
| EA (1) | EA202090617A1 (de) |
| GE (1) | GEP20237484B (de) |
| IL (1) | IL273351A (de) |
| JO (1) | JOP20200063A1 (de) |
| MA (1) | MA50156A (de) |
| MX (1) | MX2020002989A (de) |
| PH (1) | PH12020500473A1 (de) |
| SA (1) | SA520411559B1 (de) |
| SG (1) | SG11202002220TA (de) |
| TW (1) | TW201915021A (de) |
| WO (1) | WO2019057564A1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7464389B2 (ja) | 2016-08-02 | 2024-04-09 | ビステラ， インコーポレイテッド | 操作されたポリペプチドおよびその使用 |
| WO2020114616A1 (en) | 2018-12-07 | 2020-06-11 | Tillotts Pharma Ag | Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202008722QA (en) * | 2003-11-05 | 2020-10-29 | Roche Glycart Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
| ES2359567T3 (es) * | 2004-12-29 | 2011-05-24 | Yuhan Corporation | Anticuerpo humanizado específico para el factor de necrosis tumoral-alfa. |
| AU2005323025A1 (en) | 2004-12-31 | 2006-07-13 | Biogen Idec Ma Inc. | Polypeptides that bind BR3 and uses thereof |
| EP3825329A1 (de) * | 2007-12-26 | 2021-05-26 | Xencor, Inc. | Fc-varianten mit veränderter bindung zu fcrn |
| PL2307457T5 (pl) * | 2008-06-25 | 2022-12-27 | Novartis Ag | Stabilne i rozpuszczalne przeciwciała hamujące tnf |
| EP3122777B1 (de) | 2014-03-26 | 2020-12-23 | Cell Medica Switzerland AG | Anbinden von elementen an tnf-alpha |
| BR112016023948A2 (pt) * | 2014-04-16 | 2018-01-30 | Ucb Biopharma Sprl | proteínas fc multiméricas |
| CR20180365A (es) * | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| CR20180445A (es) * | 2016-03-14 | 2019-02-08 | Univ Oslo | Inmunoglobulinas diseñadas por ingeniería genética con unión alterada al fcrn |
| SI3219726T1 (sl) * | 2016-03-17 | 2021-02-26 | Tillotts Pharma Ag | Anti-TNF alfa protitelesa in njihovi funkcionalni fragmenti |
-
2017
- 2017-09-19 EP EP17191989.7A patent/EP3456738B1/de active Active
- 2017-09-19 EP EP24188725.6A patent/EP4424707A2/de active Pending
-
2018
- 2018-09-11 KR KR1020207009263A patent/KR20200053514A/ko not_active Application Discontinuation
- 2018-09-11 SG SG11202002220TA patent/SG11202002220TA/en unknown
- 2018-09-11 MX MX2020002989A patent/MX2020002989A/es unknown
- 2018-09-11 CR CR20210205A patent/CR20210205A/es unknown
- 2018-09-11 EA EA202090617A patent/EA202090617A1/ru unknown
- 2018-09-11 JP JP2020516456A patent/JP7240385B2/ja active Active
- 2018-09-11 GE GEAP201815316A patent/GEP20237484B/en unknown
- 2018-09-11 CN CN201880060497.2A patent/CN111094343B/zh active Active
- 2018-09-11 US US16/648,537 patent/US11999781B2/en active Active
- 2018-09-11 WO PCT/EP2018/074522 patent/WO2019057564A1/en active Application Filing
- 2018-09-11 BR BR112020005482-8A patent/BR112020005482A2/pt unknown
- 2018-09-11 CR CR20200132A patent/CR20200132A/es unknown
- 2018-09-11 EP EP18762890.4A patent/EP3684807A1/de active Pending
- 2018-09-11 MA MA050156A patent/MA50156A/fr unknown
- 2018-09-11 JO JOP/2020/0063A patent/JOP20200063A1/ar unknown
- 2018-09-11 CA CA3075959A patent/CA3075959A1/en active Pending
- 2018-09-11 AU AU2018337495A patent/AU2018337495B2/en active Active
- 2018-09-17 TW TW107132681A patent/TW201915021A/zh unknown
- 2018-09-19 AR ARP180102664A patent/AR113303A1/es unknown
-
2020
- 2020-03-09 PH PH12020500473A patent/PH12020500473A1/en unknown
- 2020-03-17 IL IL273351A patent/IL273351A/en unknown
- 2020-03-18 SA SA520411559A patent/SA520411559B1/ar unknown
- 2020-03-19 CL CL2020000721A patent/CL2020000721A1/es unknown
- 2020-03-19 CO CONC2020/0003260A patent/CO2020003260A2/es unknown
-
2022
- 2022-12-27 JP JP2022210008A patent/JP7402304B2/ja active Active
-
2024
- 2024-06-03 US US18/732,335 patent/US20240343793A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268517A (en) | Anti-tigit antibodies | |
| IL272227A (en) | ANTI-TIGIT antibodies | |
| IL268620A (en) | Antibodies against LAG3 | |
| IL267797B1 (en) | Anti-gpc3 antibody | |
| HUE067040T2 (hu) | Anti-SIRPalfa antitestek | |
| GB201709808D0 (en) | Antibodies | |
| SG10201914130VA (en) | GARP-TGF-β ANTIBODIES | |
| SG11202002489YA (en) | Anti-transthyretin antibodies | |
| GB201720970D0 (en) | Antibodies | |
| IL273529A (en) | Anti-PACAP antibody | |
| IL275187A (en) | Anti-alpha-synuclein antibodies | |
| IL271067A (en) | Anti-trkb antibodies | |
| RS61883B1 (sr) | Varijante antitela | |
| IL273351A (en) | antibody variants | |
| IL272951A (en) | antibody variants | |
| GB201711785D0 (en) | Antibodies | |
| GB201709592D0 (en) | Antibody | |
| GB201717006D0 (en) | Anti-OPG antibodies | |
| GB201709818D0 (en) | Antibodies | |
| GB201703071D0 (en) | Antibodies | |
| GB201701416D0 (en) | Anti-OPG antibodies |